Short interest for Cellectis gives investors a sense of the degree to which investors are betting on the decline of Cellectis's stock. Short interest data is updated every two weeks.

Cellectis Stock (NASDAQ:CLLS), Short Interest Report

Cellectis

Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ACLX

ACXP

AIRE

ALPN

AUDC

AVNW

AWRE

BHIL

CARS

CFLT

CLLS

CNTB

CRAI

CROX

DASH

DRIO

EGHT

ERII

FROG

FSLY

HOWL

HYZN

INFA

JAKK

JOBY

LMDX

LMND

LOCL

LSPD

LYFT

MCRB

NARI

NVST

OLIT

OMCL

OMGA

OPEN

OTLK

PBLA

PCOR

PKOH

PLPC

PLTR

POET

PTVE

PYPL

QCOM

QNST

RCKY

RELY

ROKU

RVLV

SABR

SBGI

SEDG

SGMO

SHOP

STAA

TENB

THTX

VIRI

XRAY

Gainers


	OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders.


Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Pre-Market Outlook

ALBT

SIEN

Gainers

LumiraDx Limited (NASDAQ: LMDX) shares surged 39.7% to $0.1143 in pre-market trading after falling 17% on Wednesday. LumiraDX recently announced the receipt of the Nasdaq delisting determination.

Why Roku Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket

Earnings

Eurozone

Commodities

Global

Federal Reserve

IRIX

PATI

PAYC

TGTX

U.S. stocks traded higher toward the end of trading, after the Federal Reserve announced its policy decision.

The Dow traded up 0.40% to 33,185.41 while the NASDAQ rose 0.92% to 12,969.54. The S&amp;P 500 also rose, gaining, 0.67% to 4,221.94.

Dow Gains Over 100 Points; Fed Leaves Interest Rates Unchanged

Cellectis S.A. - American Depositary Shares

Cellectis SA

<p>IDEAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) reported quarterly losses of $(0.53) per share which met the analyst consensus estimate.</p>


IDYA

IDEAYA Biosciences Q1 2024 GAAP EPS $(0.53), Inline

Health Care

General

OSCR

Oscar Health Reports Q1 Medical Loss Ratio Of 74.2%, With Total Members 1.44M Compared To 1.02M A Year Ago

EVEX

Eve Holding Reports Q1 FY24 Net Loss Of $(25.3)M

<p>Squarespace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQSP#NYSE">SQSP</a>) reported quarterly sales of $281.148 million which beat the analyst consensus estimate of $276.327 million by 1.74 percent.  This is a 18.61 percent increase over sales of $237.028 million the same period last year.</p>


Earnings Beats

SQSP

Squarespace Q1 Sales $281.148M Beat $276.327M Estimate

<p>HC Wainwright &amp; Co.  analyst Mitchell Kapoor   initiates coverage on Metagenomi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGX#NASDAQ">MGX</a>) with a Buy rating and announces Price Target of $10.</p>


Price Target

Initiation

Analyst Ratings

HC Wainwright & Co. Initiates Coverage On Metagenomi with Buy Rating, Announces Price Target of $10

<p>Today, GEO updated initial financial&nbsp;guidance&nbsp;for 2024. For the full year 2024, expects Net Income to be in a range of&nbsp;$55 million&nbsp;to&nbsp;$75 million (prior view $110 million&nbsp;to&nbsp;$125 million) and reflecting an effective tax rate of approximately&nbsp;20 percent, inclusive of known discrete items. Full-year 2024&nbsp;guidance&nbsp;reflects an&nbsp;$86 million&nbsp;loss on extinguishment of debt, pre-tax, as a result of refinancing transactions during the&nbsp;second quarter&nbsp;of 2024. It expects&nbsp;full year 2024 Adjusted EBITDA to be between&nbsp;$485 million&nbsp;and&nbsp;$515 million.</p>


Guidance

GEO Group Continues To See Annual Revenues Of Approximately $2.4B, Est $2.45B

HSIC

Henry Schein Expects 2024 Sales Growth Of Approximately 8%-10% Compared To Prior Growth Guidance Of 8%-12%

Knife River Reaffirms FY24 Revenue Of $2.75B-$2.95B (Vs. $2.88B Est.)

<p>HC Wainwright &amp; Co.  analyst Amit Dayal   reiterates Alto Ingredients (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTO#NASDAQ">ALTO</a>) with a Buy and maintains $5.5 price target.</p>


Reiteration

ALTO

HC Wainwright & Co. Reiterates Buy on Alto Ingredients, Maintains $5.5 Price Target

<p>Deutsche Bank  analyst Brad Zelnick   maintains Palantir Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) with a Sell and raises the price target from $18 to $20.</p>


Deutsche Bank Maintains Sell on Palantir Technologies, Raises Price Target to $20

<p>2024 Adjusted EBITDA&nbsp;is expected to increase by more than 15% compared with 2023, unchanged from prior guidance</p>


Henry Schein Reaffirms 2024 Adjusted EPS Guidance Of $5.00-$5.16 Versus Consensus Of $5.06

<p><strong>Full-Year&nbsp;Outlook1</strong></p>
<p>The Company is adjusting its estimate for fiscal year 2024 Adjusted EBITDA to be approximately&nbsp;$850 million&nbsp;to&nbsp;$900 million, and adjusting its estimate for Adjusted net income per diluted share to&nbsp;$16.00&nbsp;-&nbsp;$17.00.</p>


ATKR

Atkore 2024 Outlook, Lowered: Now Expects Adjusted EPS Of $16.00-$17.00 (Prior $16.50-$17.50); Est. $16.93; Sees Adjusted EBITDA of $850M to $900M

Oscar Health Q1 2024 GAAP EPS $0.62 May Not Be Comparable To $0.26 Estimate, Sales $2.142B Beat $2.011B Estimate

<p>Knife River Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNF#NYSE">KNF</a>) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(0.86) by 2.33 percent.  The company reported quarterly sales of $329.600 million which beat the analyst consensus estimate of $300.984 million by 9.51 percent.</p>


Knife River Holding Q1 2024 GAAP EPS $(0.84) Beats $(0.86) Estimate, Sales $329.600M Beat $300.984M Estimate

ESPR

Esperion Therapeutics Sees FY24 Revenues $225M-$245M, Including $20M In Non-cash Expenses Related To Stock Compensation

<p>X4 Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XFOR#NASDAQ">XFOR</a>) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.16) by 62.5 percent. This is a 62.5 percent decrease over losses of $(0.16) per share from the same period last year.</p>


Earnings Misses

XFOR

X4 Pharmaceuticals Q1 2024 GAAP EPS $(0.26) Misses $(0.16) Estimate

<p>For the&nbsp;second quarter&nbsp;of 2024, GEO expects a Net Loss in a range of&nbsp;$27 million&nbsp;to&nbsp;$30&nbsp;millionas a result of the&nbsp;$86 million&nbsp;loss on extinguishment of debt, pre-tax, during the&nbsp;second quarter&nbsp;of 2024. It expects second quarter&nbsp;2024 Adjusted EBITDA to be in a range of&nbsp;$119 million&nbsp;to&nbsp;$125 million.</p>


GEO Group Expects Q2 Revenues Of $600M-$610M, Est $608.851M

Modine To Open Additional UK Facility To Meet Data Center Market Demand

<p>Henry Schein (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSIC#NASDAQ">HSIC</a>) reported quarterly earnings of $1.10 per share which beat the analyst consensus estimate of $1.01 by 8.91 percent.  The company reported quarterly sales of $3.172 billion which missed the analyst consensus estimate of $3.210 billion by 1.20 percent.  This is a 3.66 percent increase over sales of $3.060 billion the same period last year.</p>


Henry Schein Q1 2024 Adj EPS $1.10 Beats $1.01 Estimate, Sales $3.172B Miss $3.210B Estimate

<p>Esperion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESPR#NASDAQ">ESPR</a>) reported quarterly earnings of $0.34 per share which beat the analyst consensus estimate of $0.05 by 580 percent. This is a 143.04 percent increase over losses of $(0.79) per share from the same period last year.  The company reported quarterly sales of $137.74 million which beat the analyst consensus estimate of $84.51 million by 62.98 percent.  This is a 466.14 percent increase over sales of $24.33 million the same period last year.</p>


Esperion Therapeutics Q1 EPS $0.34 Beats $0.05 Estimate, Sales $137.74M Beat $84.51M Estimate

Cellectis S.A. (CLLS) has released an update. Cellectis S.A., a biotech firm, has announced breakthroughs in gene-editing technology that could sig...

Cellectis Unveils Groundbreaking Gene-Editing Advances

Cellectis GAAP EPS of -$0.64 misses by $0.43, revenue of $1.99M misses by $14.13M

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Cellectis</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/clls-stock-quote/"><strong>CLLS</strong></a></span>) just reported results for the fourth quarter of 2023.</p><ul><li>Cellectis reported earnings per share of -57 cents. This was below the analyst estimate for EPS of -22 cents.</li><li>The company reported revenue of $1.99 million.</li><li>This was 87.76% worse than the analyst estimate for revenue of $16.26 million.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/04/clls-stock-earnings-cellectis-for-q4-of-2023/">CLLS Stock Earnings: Cellectis Misses EPS, Misses Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

CLLS Stock Earnings: Cellectis Misses EPS, Misses Revenue for Q4 2023

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Healthequity (HQY – Research Report), Cellectis SA (...

Analysts Offer Insights on Healthcare Companies: Healthequity (HQY), Cellectis SA (CLLS) and Idexx Laboratories (IDXX)

Barclays analyst Gena Wang maintained a Buy rating on Cellectis SA (CLLS – Research Report) today and set a price target of $7.00. The company's sh...

Barclays Remains a Buy on Cellectis SA (CLLS)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Qiagen (QGEN – Research Report), Inari Medical (NARI...

Analysts Are Bullish on Top Healthcare Stocks: Qiagen (QGEN), Inari Medical (NARI)

Cellectis announces CFO departure

Cellectis SA (CLLS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Silvan Tuerkcan from JM...

Cellectis SA: Strong Investment and Clinical Progress Signaling a Market Outperform Rating

Cellectis S.A. (CLLS) has released an update. Cellectis S.A., a clinical-stage biotechnology company, has completed a substantial $140M equity inve...

Cellectis Bolstered by $140M AstraZeneca Investment

AstraZeneca invests $140M in Cellectis, raising stake to 44%

CMVLF

IDXX

QGEN

Press Releases

Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca

Cellectis' Shareholders Meeting to be Held on December 22, 2023

Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023

Cellectis announces the drawdown of the second tranche of €15 million under the credit facility agreement entered with the European Investment Bank (EIB)

Cellectis Announces Two Poster Presentations on Novel TALEN® Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting

Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs

Cellectis Presents Novel TALEN® Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023

Cellectis Appoints Arthur Stril as Interim Chief Financial Officer

Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cellectis Stock (NASDAQ:CLLS), Short Interest Report

People Also Watch